{"testuser": {"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"]}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "999"}, {"clin_sig": "Pathogenic", "lab_name": "NIHR Bioresource Rare Diseases, University of Cambridge", "comment": "nan", "report_date": "2019-02-01", "labrank": "999"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "999"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "999"}, {"clin_sig": "Pathogenic", "lab_name": "CeGaT Praxis fuer Humangenetik Tuebingen", "comment": "nan", "report_date": "2019-09-01", "labrank": "999"}], [{"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "999"}], [{"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "999"}], [{"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "999"}], [{"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "999"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Fraction": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}, "PDE6H c.35C>G": {"Gene Data": {"Number": 2, "Classification": "Conflicting interpretations of pathogenicity", "Gene": "PDE6H", "Exon/Intron": "1", "SNP ID": "rs200311463", "DNA change": "c.35C>G", "Protein change": "p.Ser12Ter", "Transcript ID": "ENST00000266395.3", "Zygosity": "heterozygous", "Inheritance": "not given", "Associated Disease(s)": ["PDE6H-Related Disorders", "Retinal cone dystrophy 3A", "Achromatopsia 6"], "Cancer Groups": ["HEMATOLOGIC"]}, "Comments": [[{"clin_sig": "Conflicting interpretations of pathogenicity", "lab_name": "Illumina Clinical Services Laboratory,Illumina", "comment": "The PDE6H c.35C>G (p.Ser12Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Ser12Ter variant has been reported in two studies and is found in a homozygous state in five probands from three families including two sibling pairs (Kohl et al. 2012; Pedurupillay et al. 2016). Three of the probands are diagnosed with incomplete achromatopsia and two with cone dystrophy. The unaffected parents of the siblings were confirmed heterozygotes for the p.Ser12Ter variant. The p.Ser12Ter variant was absent from 180 control subjects and is reported at a frequency of 0.000166 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the potential impact of stop-gained variants and evidence from the literature, the p.Ser12Ter variant is classified as likely pathogenic for PDE6H-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.", "report_date": "2018-08-23", "labrank": "999"}], [{"clin_sig": "Conflicting interpretations of pathogenicity", "lab_name": "Illumina Clinical Services Laboratory,Illumina", "comment": "The PDE6H c.35C>G (p.Ser12Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Ser12Ter variant has been reported in two studies and is found in a homozygous state in five probands from three families including two sibling pairs (Kohl et al. 2012; Pedurupillay et al. 2016). Three of the probands are diagnosed with incomplete achromatopsia and two with cone dystrophy. The unaffected parents of the siblings were confirmed heterozygotes for the p.Ser12Ter variant. The p.Ser12Ter variant was absent from 180 control subjects and is reported at a frequency of 0.000166 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the potential impact of stop-gained variants and evidence from the literature, the p.Ser12Ter variant is classified as likely pathogenic for PDE6H-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.", "report_date": "2018-08-23", "labrank": "999"}], [{"clin_sig": "Conflicting interpretations of pathogenicity", "lab_name": "Illumina Clinical Services Laboratory,Illumina", "comment": "The PDE6H c.35C>G (p.Ser12Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Ser12Ter variant has been reported in two studies and is found in a homozygous state in five probands from three families including two sibling pairs (Kohl et al. 2012; Pedurupillay et al. 2016). Three of the probands are diagnosed with incomplete achromatopsia and two with cone dystrophy. The unaffected parents of the siblings were confirmed heterozygotes for the p.Ser12Ter variant. The p.Ser12Ter variant was absent from 180 control subjects and is reported at a frequency of 0.000166 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the potential impact of stop-gained variants and evidence from the literature, the p.Ser12Ter variant is classified as likely pathogenic for PDE6H-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.", "report_date": "2018-08-23", "labrank": "999"}]], "Frequencies": {"Gene": "PDE6H", "Transcript": "ENST00000266395.3", "DNA change": "c.35C>G", "Protein change": "p.Ser12Ter", "Genomic Location": "chr12:14978047", "Alternate Allele Fraction": "0.01%", "dbSNP rsID": "rs200311463"}, "Publications": [{"Pubmed ID": "20301591", "Title": "Achromatopsia"}, {"Pubmed ID": "22901948", "Title": "A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia."}, {"Pubmed ID": "27472364", "Title": "Segregation of Incomplete Achromatopsia and Alopecia Due to PDE6H and LPAR6 Variants in a Consanguineous Family from Pakistan."}]}}}